GILDQueued from the May 25, 2026 S&P 500 market-cap snapshot ranks 51-75.

Gilead Sciences

Gilead Sciences is a U.S. biopharmaceutical company focused on HIV, liver disease, oncology, inflammation, and other serious diseases.

CompaniesMarketCap Product analyses

Metadata

Where this company sits

Ticker: GILD
Rank snapshot: ≈ 60
Sector: Health Care
Industry: Pharmaceuticals
Region: United States
Index: S&P 500 · Top 75 by market cap

Metrics

Scoring view

Every metric is paired with a short rationale. The numbers are deliberate, not divine.

Moat

8.0/10

Gilead combines approved medicines, clinical evidence, regulatory exclusivity and patents, specialist prescriber relationships, payer access, manufacturing controls, and a large HIV franchise. Those barriers make direct substitution difficult even when upstream science becomes more open.

Decentralizability

2.0/10

Finished prescription drugs are tightly regulated and require validated manufacturing, prescribing, safety monitoring, and quality systems. Decentralization is more plausible in discovery, evidence generation, and post-market monitoring than in unsupervised replacement of the medicine.

Profitability

8.0/10

Recent financial summaries show a large profitable biopharmaceutical business with roughly $29.44 billion of 2025 revenue and continued earnings power, though results remain exposed to product mix, acquired R&D charges, pipeline outcomes, and Veklury normalization.

Price / Earnings

18.1x

StockAnalysis reported a P/E ratio of about 18.10 in its current GILD snapshot around the review date; market-data figures fluctuate with price and earnings updates.

Market cap

$165.2B

StockAnalysis reported Gilead's market capitalization at about $165.19 billion near the review date, while other market-data sources showed nearby values in the same range.

Freed-up capital potential

$10.5B

Derived from market cap, moat resistance, decentralizability, and profitability. It is a directional estimate of value capture that could come under pressure if open alternatives compound.

Narrative

Why the company matters

A short editorial overview plus the current thesis on moat strength and decentralization pressure.

Business mix

Gilead's commercial base is anchored by HIV medicines, led by Biktarvy, while oncology growth is supported by Trodelvy and cell-therapy assets.

The company also sells liver-disease products and Veklury, but the investment case is increasingly tied to durable HIV cash flow, oncology pipeline execution, and protection from near-term loss of exclusivity.

Registry relevance

For Free The World, Gilead is a useful pharmaceutical incumbent because its moat is built from regulated clinical evidence, manufacturing quality systems, physician trust, intellectual property, reimbursement access, and global commercialization capacity.

Those strengths are difficult to decentralize at the finished-drug level, but open discovery, federated clinical evidence, and shared manufacturing or pharmacovigilance infrastructure can pressure parts of the upstream and post-market stack.

Moat reading

Gilead's moat is strong because prescription medicines require clinical evidence, regulatory approvals, manufacturing controls, pharmacovigilance, payer access, and physician confidence before they can be substituted. Biktarvy is a leading HIV regimen and Trodelvy is an approved antibody-drug conjugate in serious oncology indications, giving the company high switching friction where patients and clinicians prioritize validated outcomes.

The moat is not absolute. Pharmaceutical revenue can face patent cliffs, payer pressure, clinical trial setbacks, and competitive treatment innovation. Still, Gilead's public disclosures point to a large product-sales base, continued HIV franchise strength, and management commentary that no major loss of exclusivity is expected until 2036.

Decentralization reading

Finished medicines like Biktarvy and Trodelvy are among the hardest product categories to decentralize because safety, efficacy, batch consistency, cold-chain or specialty handling, prescribing, and adverse-event surveillance are regulated activities. A peer-to-peer replacement for the drug itself would be unsafe and noncompliant.

The more credible decentralization path is upstream and around the product: open target discovery, open computational chemistry, federated patient registries, decentralized evidence generation, and cooperative trial infrastructure. These can reduce dependence on closed pharmaceutical pipelines without pretending that regulated medicine can become casual local production.

Products

Where the moat actually touches users

These pages zoom into the products and services that matter most to each company, the alternatives already nibbling at them, and 4 structured disruption concepts across the current product set.

4 disruption concepts tracked0 documented exceptions

Biktarvy

HIV treatment

2 concepts

Biktarvy is Gilead's single-tablet HIV-1 treatment regimen combining bictegravir, emtricitabine, and tenofovir alafenamide.

Open analysis

Trodelvy

Oncology antibody-drug conjugate

2 concepts

Trodelvy is Gilead's sacituzumab govitecan-hziy therapy, a Trop-2-directed antibody-drug conjugate used in certain metastatic breast-cancer settings.

Open analysis

Technology waves

Strategic lenses

These are the repo's explicit bias terms: the technologies expected to keep making incumbents less inevitable over time.

Bitcoin and Lightning as coordination rails

Proof-of-work economics, programmable payment flows, and anti-spam pricing make more digital systems capable of rewarding signal while resisting abuse.

• Platforms that monetize gatekeeping could face pressure from protocol-native payment and reputation layers.
• Micropayments can replace some ad-funded or subscription-heavy distribution models.
• Open systems with credible anti-spam economics deserve a higher decentralizability score than legacy software assumptions suggest.

Paper trail